Akebia Therapeutics, Inc. AKBA
0.39 USD -0.04 (-8.71%)
Regular-session close
0.40 +0.01 +3.50%
After hours · Nov 20, 7:50 PM ET
0.3849 Day range 0.4331
0.3855 52-week range 1.70
- YTD
- -76.06%
- 1 year
- -74.97%
News
globenewswire.com Akebia Therapeutic's Vafseo® (vadadustat) Granted Additional Patent New patent with term until 2043 further strengthens patent portfolio WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the…benzinga.com Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $2 Piper Sandler analyst Allison Bratzel maintains Akebia Therapeutics (NASDAQ:AKBA) with a Overweight and lowers the price target from $4 to $2.
globenewswire.com Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million Initial $60 million tranche fully funded, proceeds of which were used to fully repay $55 million BlackRock loan facility
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…benzinga.com HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4 HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $6 to $4.
benzinga.com BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3 BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com Akebia Therapeutics Q3 2026 Earnings Call Transcript Akebia Therapeutics (NASDAQ:AKBA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Akebia Therapeutics Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $36.900M Miss $46.941M Estimate Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $36.900…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…benzinga.com Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s…
